Literature DB >> 2540789

Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Report to the Medical Research Council by its Lung Cancer Working Party.

.   

Abstract

A total of 497 patients with histologically or cytologically confirmed small-cell lung cancer were prescribed initial treatment with six courses of etoposide, cyclophosphamide, methotrexate and vincristine at 3-week intervals. Patients with limited disease (74% of the total) also received radiotherapy (40 Gy in 15 fractions in 3 weeks) to the primary site between courses 2 and 3. At the end of this initial treatment, 265 patients still in complete or partial response were randomly allocated to six further courses of maintenance chemotherapy (M series: 131 patients) or to no maintenance chemotherapy (NoM series: 134 patients). Response, as assessed 3 weeks after the second course of initial chemotherapy, was achieved in 85% of the 264 patients assessed, a complete response in 11%. The median survival period from the date of start of chemotherapy was 39 weeks; 154 (31%) of the patients were alive at 1 year, 29 (6%) at 2 years and 17 (3%) at 3 years. The patients' general condition and extent of disease pretreatment correlated significantly with survival. Among the 131 M and 134 NoM patients there was no overall survival advantage to either series (P = 0.27, log rank test), although in 99 patients who had a complete response to initial chemotherapy as assessed at the time of randomisation there was a suggestion that survival was longer in the M series (P less than 0.05, log rank test), the median survival periods from the date of randomisation being 42 weeks for the M and 30 weeks for the NoM patients. Maintenance chemotherapy was associated with additional toxicity and a poorer quality of life as assessed intermittently by clinicians and daily by patients. In conclusion, no worthwhile clinical advantage was achieved by the policy of continuing chemotherapy beyond six courses, except possibly in patients with a complete response to the initial six courses.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2540789      PMCID: PMC2247128          DOI: 10.1038/bjc.1989.118

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  6 in total

Review 1.  Chemotherapy of small-cell lung cancer.

Authors:  F A Greco; D H Johnson; J D Hainsworth; S N Wolff
Journal:  Semin Oncol       Date:  1985-12       Impact factor: 4.929

2.  Combined modality treatment of small cell carcinoma of the lung.

Authors:  R Feld; J F Pringle; W K Evans; C W Keen; I C Quirt; J E Curtis; M A Baker; J L Yeoh; G Deboer; T C Brown
Journal:  Arch Intern Med       Date:  1981-03

Review 3.  Measuring and analysing quality of life in cancer clinical trials: a review.

Authors:  P M Fayers; D R Jones
Journal:  Stat Med       Date:  1983 Oct-Dec       Impact factor: 2.373

4.  Combined modality induction therapy without maintenance chemotherapy for small cell carcinoma of the lung.

Authors:  R Feld; W K Evans; G DeBoer; I C Quirt; F A Shepherd; J L Yeoh; J F Pringle; D G Payne; J G Herman; D Chamberlain
Journal:  J Clin Oncol       Date:  1984-04       Impact factor: 44.544

5.  Maintenance chemotherapy for anaplastic small cell carcinoma of the bronchus: a randomised, controlled trial.

Authors:  M Cullen; D Morgan; W Gregory; M Robinson; D Cox; D McGivern; M Ward; M Richards; D Stableforth; A Macfarlane
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

6.  Patient subsets and variation in therapeutic efficacy.

Authors:  R Simon
Journal:  Br J Clin Pharmacol       Date:  1982-10       Impact factor: 4.335

  6 in total
  13 in total

1.  Economic and quality-of-life aspects of treating small cell lung cancer.

Authors:  P Graham; J Boyages
Journal:  Pharmacoeconomics       Date:  1993-06       Impact factor: 4.981

2.  Quality-of-life assessment in small cell lung cancer.

Authors:  P Fayers
Journal:  Pharmacoeconomics       Date:  1992-09       Impact factor: 4.981

Review 3.  Carcinoma of the bronchus 60 years later.

Authors:  G A Silvestri; S G Spiro
Journal:  Thorax       Date:  2006-12       Impact factor: 9.139

Review 4.  SEOM clinical guidelines for the treatment of small-cell lung cancer 2013.

Authors:  M Dómine Gómez; T Morán Bueno; A Artal Cortés; J Remon Masip; P Lianes Barragán
Journal:  Clin Transl Oncol       Date:  2013-09-05       Impact factor: 3.405

5.  Approaches to the analysis of quality of life data: experiences gained from a medical research council lung cancer working party palliative chemotherapy trial.

Authors:  P Hopwood; R J Stephens; D Machin
Journal:  Qual Life Res       Date:  1994-10       Impact factor: 4.147

Review 6.  Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Authors:  J M Henwood; R N Brogden
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

7.  Is the progress in cancer treatment results adequate or are we confronted with a more or less worldwide stagnation.

Authors:  K Karrer
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

Review 8.  MRC quality of life studies using a daily diary card--practical lessons learned from cancer trials.

Authors:  P Fayers
Journal:  Qual Life Res       Date:  1995-08       Impact factor: 4.147

Review 9.  Modern management of small-cell lung cancer.

Authors:  Roberta Ferraldeschi; Sofia Baka; Babita Jyoti; Corinne Faivre-Finn; Nick Thatcher; Paul Lorigan
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 10.  Extensive stage small cell lung cancer.

Authors:  H B Niell
Journal:  Curr Treat Options Oncol       Date:  2001-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.